Irvine Biomedical, Inc. appears in FDA device records as the applicant for P040014, approved on January 14, 2005 for the IBI Therapy Cardiac Ablation System. The Summary of Safety and Effectiveness Data identifies the device generic name as Cardiac Radio Frequency (RF) Ablation System and lists the applicant at 2375 Morse Ave., Irvine, CA 92614, an address that appears in the filing rather than as a verified corporate headquarters. The supplied collection covers two linked PMA records, both under P040014 and product code LPB, with decision codes APPR and OK30. [1][2][6]
The approved system and its stated indication
The original approval record describes the trade name as IBI Therapy Cardiac Ablation System, ERS/1500T RF Generator, with generic name Cardiac ablation percutaneous catheter and device class 3 under product code LPB. The approval statement says the device is indicated for mapping and for use with a compatible RF generator for interruption of accessory atrioventricular conduction pathways associated with tachycardia, treatment of AV nodal re-entrant tachycardia, or creation of complete AV nodal block in patients with a difficult to control ventricular response to an atrial arrhythmia. The Summary of Safety and Effectiveness Data repeats the mapping and compatible-RF-generator framing and directs readers to final labeling for indications, contraindications, warnings, precautions and adverse events. [2][6]
The advisory committee is recorded as Cardiovascular, and the expedited review flag is recorded as N. The approval notice date is January 14, 2005, with a Federal Register notice date of March 9, 2005 and docket number 05M-0088. [2]
A 2026 supplement to the catheter manufacturing process
Supplement S052 to P040014 covers the Therapy (including Bi-Directional and 4mm Thermistor) Ablation Catheter. It is a 30-Day Notice with supplement reason Process Change - Manufacturer/Sterilizer/Packager/Supplier, received August 7, 2026 and decided September 3, 2026 with decision code OK30. The approval order statement describes the change as adding an alternate epoxy in the manufacture of the temperature sensor. [1]
The supplement record keeps the same product code LPB, generic name Cardiac ablation percutaneous catheter, device class 3 and Cardiovascular advisory committee as the original approval, and it carries the same Irvine, CA 92614 address for the applicant. [1][2]
How the linked FDA records relate
Both linked records sit in the PMA pathway under P040014. The full supplied collection shows one APPR decision and one OK30 decision, and the explicitly smaller recordSample of two entries shows the same split of one APPR and one OK30. These counts describe the supplied filings only and are not measures of total portfolio, sales or safety performance. [1][2]
The FDA PMA page for P040014 notes that the device has supplements and that the device description, function or indication may have changed, so the supplements should be consulted for current information. No recall records appear in the supplied sample. [5][9]
Identity and limits of the record
The applicant name on the filings is Irvine Biomedical, Inc., and the Summary of Safety and Effectiveness Data abbreviates it as IBI. The public documents do not establish a parent company, brand ownership, website, customer base or commercial availability, and the filing address is not treated here as a verified headquarters. [6][7]
The establishment registration and device listing page and the PMA pages in the supplied set provide database navigation and page-update information rather than additional product specifications. Details beyond the documented system, catheter supplement and stated indication remain unknown from these sources. [4][8]
